The review timeline for FDA medical device registration can vary widely depending on several factors, including the device's classification, the type of submission (e.g., 510(k), PMA), the completeness of the application, and FDA's current workload. Generally, FDA strives to review and provide feedback on submissions within specific timeframes outlined by law and guidance documents.
510(k) Premarket Notification: For moderate-risk devices (Class II), the FDA aims to review 510(k) submissions within 90 days of submission. However, this timeframe can be longer if additional information or clarification is required during the review process.
Premarket Approval (PMA): High-risk devices (Class III) requiring PMA typically undergo a more rigorous review process, which may include extensive clinical data evaluation. FDA's goal is to complete PMA reviews within 180 days, although the actual review time can vary significantly based on the complexity of the device and the sufficiency of the data provided.
De Novo Classification Requests: Devices seeking classification under the De Novo pathway, which are not substantially equivalent to any existing device, undergo a review process that may take up to 150 days. This timeframe includes both FDA's review of the request and the determination of appropriate classification.
Other Factors: Additional factors influencing review timelines include the submission of complete and well-organized documentation, responsiveness to FDA inquiries or requests for additional information, and the occurrence of any regulatory or administrative delays.
It's important for manufacturers to engage with FDA early in the process, through pre-submission meetings and other interactions, to clarify regulatory requirements and streamline the review process. Proactively addressing potential issues and ensuring compliance with FDA's Quality System Regulation (QSR) and other applicable regulations can help expedite the review and approval of medical devices.
Overall, while FDA strives to adhere to these review timelines, actual approval times can vary based on the specifics of each submission. Manufacturers should plan accordingly and maintain open communication with FDA to facilitate a timely and successful registration process for their medical devices in the United States.
Contact Us:
Whatsapp or Wechat:+86 15816864648;email address:hito.lin@grzan.cn
Grzan News
Tel:0755-33509057
Adress:Room 103-108, Building B, Block 2, Bangkai Science and Technology Park, No. 9, Guangyuan 5th Road, Fenghuang Street, Guangming District, Shenzhen City, Guangdong Province, China.
E-mail:hitolin@grzan.com
Grzan medical can undertake the whole process of technical guidance and services such as prospective clinical, who Eul, variant virus research (Delta, Omicron ba.1, ba.2), IVDD CE, ivdr CE, Australian TGA, British CTDA, European HSC common list, European service, British service, etc.
If you have products that have been tested and certified or want to know more about them, please contact Grzan medical!
Popular keywords:UK authorised representative CTDA registration HSC EU common list Canada cmdcas certification Canadian del certification Australian TGA certification Registered in Hong Kong Medical device certification Variant strain test Who Eul application IVDD CE certification IVDR CE认证 EU authorized representative SRN registration Ukca certification
友 情 链 接:国瑞质量检验中心
Copyright © Grzan medical technology (SZ) Co., Ltd All rights reserved